<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046459</url>
  </required_header>
  <id_info>
    <org_study_id>BNZ-CT-101</org_study_id>
    <nct_id>NCT03046459</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of BNZ132-1-40</brief_title>
  <official_title>A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioniz Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bioniz Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single ascending dose study to characterize the safety and PK/PD
      profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2
      family.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label study of single doses of intravenous BNZ132-1-40 administered to healthy
      adult subjects. Subjects are followed for 30 days after treatment for collection of safety,
      PK and PD data. Cohorts of up to 6 subjects will be enrolled for each dose level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 5, 2017</completion_date>
  <primary_completion_date type="Actual">June 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with related, treatment-emergent adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Exposure as determined by maximum plasma concentration (Cmax)</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Exposure as determined by area under the concentration-time curve (AUC)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Effects of BNZ132-1-40 on the expression of T cells as determined by FACS analysis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BNZ132-1-40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a range of IV doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNZ132-1-40</intervention_name>
    <description>pegylated peptide inhibiting IL-2, IL-9 and IL-15</description>
    <arm_group_label>BNZ132-1-40</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and non-pregnant, non-lactating females

          -  no ongoing clinically significant medical condition

          -  willing and able to provide informed consent

          -  no use of Rx or OTC medications, other than oral contraceptives

        Exclusion Criteria:

          -  Recent systemic infections

          -  Clinically-significant abnormal clinical labs, ECG or physical examination

          -  Immunization 30 days prior to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Frohna, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bioniz Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jbc.org/content/290/37/22338.long</url>
    <description>Research paper supporting the targeting of multiple cytokines with peptide antagonists</description>
  </link>
  <reference>
    <citation>Nata T, Basheer A, Cocchi F, van Besien R, Massoud R, Jacobson S, Azimi N, Tagaya Y. Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum. J Biol Chem. 2015 Sep 11;290(37):22338-51. doi: 10.1074/jbc.M115.661074. Epub 2015 Jul 16.</citation>
    <PMID>26183780</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytokines</keyword>
  <keyword>interleukin-2</keyword>
  <keyword>Safety Issues</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

